Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) VP Jaye Thompson acquired 800 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $13.85 per share, for a total transaction of $11,080.00. Following the completion of the purchase, the vice president now directly owns 263,148 shares in the company, valued at $3,644,599.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Jaye Thompson also recently made the following trade(s):
- On Friday, August 2nd, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $15.15 per share, with a total value of $15,150.00.
- On Thursday, July 18th, Jaye Thompson purchased 1,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $16.00 per share, for a total transaction of $16,000.00.
Greenwich LifeSciences Stock Down 2.0 %
NASDAQ GLSI opened at $14.17 on Thursday. Greenwich LifeSciences, Inc. has a 52 week low of $7.58 and a 52 week high of $21.44. The business has a 50 day moving average price of $14.58 and a 200-day moving average price of $15.12. The company has a market cap of $182.51 million, a price-to-earnings ratio of -19.68 and a beta of 1.61.
Hedge Funds Weigh In On Greenwich LifeSciences
A number of hedge funds and other institutional investors have recently made changes to their positions in GLSI. Vanguard Group Inc. increased its holdings in Greenwich LifeSciences by 0.6% during the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after buying an additional 1,420 shares during the last quarter. Rhumbline Advisers purchased a new position in Greenwich LifeSciences in the second quarter valued at about $117,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Greenwich LifeSciences during the 2nd quarter valued at approximately $264,000. 4.16% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Separately, HC Wainwright boosted their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, August 23rd.
View Our Latest Research Report on GLSI
About Greenwich LifeSciences
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Stories
- Five stocks we like better than Greenwich LifeSciences
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Spread Your Bets: Winning the AI Race With Energy ETFs
- The Most Important Warren Buffett Stock for Investors: His Own
- Intuitive Machines Soars: NASA Contract Fuels Lunar Ambitions
- Transportation Stocks Investing
- 3 Beaten-Down Stocks Ready for a Comeback
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.